Lantheus Holdings, Inc. (LNTH)
| Market Cap | 6.56B +72.6% |
| Revenue (ttm) | 1.56B +2.3% |
| Net Income | 275.31M +1.6% |
| EPS | 4.15 +10.1% |
| Shares Out | 65.27M |
| PE Ratio | 24.19 |
| Forward PE | 17.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 476,241 |
| Open | 100.50 |
| Previous Close | 100.32 |
| Day's Range | 100.24 - 100.50 |
| 52-Week Range | 50.16 - 111.86 |
| Beta | 0.02 |
| Analysts | Hold |
| Price Target | 106.99 (+6.5%) |
| Est. Earnings | Nov 13, 2026 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o... [Read more]
Financial Performance
In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for LNTH stock is "Hold." The 12-month stock price target is $106.99, which is an increase of 6.50% from the latest price.
News
Lantheus downgraded to Neutral from Outperform at Mizuho
Mizuho downgraded Lantheus (LNTH) to Neutral from Outperform with a price target of $109, down from $115, after Curium agreed to acquire all of the outstanding shares of Lantheus for…
Lantheus downgraded to Neutral from Outperform at Mizuho
Mizuho downgraded Lantheus (LNTH) to Neutral from Outperform.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
BALA CYNWYD, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus announces CMS granted TPT payment status for PYLARIFY TruVu injection
Lantheus (LNTH) Holdings announced that the Centers for Medicare & Medicaid Services, CMS, has granted Transitional Pass-Through, TPT, payment status for PYLARIFY TruVu injection, effective October 1,...
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent Designation, together with a...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Lantheus announces first patient dosed in Phase 2/3 trial of LNTH-2401
Lantheus (LNTH) announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluating LNTH-2401. LNTH-2401 is an investigational gallium-68-labeled positr...
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program ...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Lantheus announces U.S. FDA granted final approval for Bravnesta
Lantheus (LNTH) announced that the U.S. Food and Drug Administration, FDA, has granted final approval for Bravnesta, a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera. Br...
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinician...
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on September 17, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on September 8, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus downgraded to Neutral from Buy at B. Riley
B. Riley downgraded Lantheus (LNTH) to Neutral from Buy with a price target of $105.40, down from $129, after Curium agreed to acquire all of the outstanding shares of Lantheus…
Lantheus announces FDA approval of Tauklarify
Lantheus (LNTH) announced FDA approval of Tauklarify, also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography of the brain in adults with cognitive impairment w...
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease
BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians...
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 13, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Earnings release: Q2 2026
Lantheus Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Lantheus Holdings Quarterly report: Q2 2026
Lantheus Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Lantheus reports Q2 adjusted EPS $1.55, consensus $1.30
Reports Q2 revenue $388.2M, consensus $363.23M. The company said, “In addition, and as previously announced, Lantheus (LNTH) entered into a definitive agreement on August 3, 2026 to merge with Curium…
Lantheus Reports Second Quarter 2026 Financial Results
Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per sh...